Adeno-Associated Virus Delivery Limitations for Neurological Indications

Authors
Benatti, Hector Ribeiro
Gray-Edwards, Heather L
UMass Chan Affiliations
Horae Gene Therapy Center
Radiology
Document Type
Editorial
Publication Date
2022-01-17

Metadata
Show full item record
Link to Full Text
https://doi.org/10.1089/hum.2022.29196.hrb
Abstract
In this commentary we discuss pitfalls and limitations of current adeno-associated virus (AAV) delivery routes, dose scaling, and the extrapolation of animal data to first-in-human (FIH) AAV clinical trials.
Source
Benatti HR, Gray-Edwards HL. Adeno-Associated Virus Delivery Limitations for Neurological Indications. Hum Gene Ther. 2022 Jan;33(1-2):1-7. doi: 10.1089/hum.2022.29196.hrb. PMID: 35049369.
DOI
10.1089/hum.2022.29196.hrb
Permanent Link to this Item
http://hdl.handle.net/20.500.14038/51576
PubMed ID
35049369
Collections